South Korea’s daily COVID-19 cases down for four straight days | Inquirer News

South Korea’s daily COVID-19 cases down for four straight days

/ 02:53 PM March 27, 2022

S. Korea’s daily COVID-19 cases down for four straight days

A health care worker collects a swab sample from a visitor to a testing facility in central Seoul, Sunday. (Yonhap via The Korea Herald/Asia News Network)

SEOUL — South Korea’s daily COVID-19 cases have decreased for four straight days, according to data reported by the country’s health authorities, Sunday.

According to the Korea Disease Control and Prevention Agency, the country added 318,130 COVID-19 infections during the 24 hours of Saturday, staying below 400,000 for the fourth consecutive day. The total caseload reached 11,815,841.

Article continues after this advertisement

The country’s daily COVID-19 cases have been decreasing since Wednesday when the country reported 490,707 COVID-19 cases.

FEATURED STORIES

The daily tally reported on Sunday was also down from the figures reported on previous Sundays, 334,642 on March 20 and 350,168 on March 13.

The government currently sees the Omicron wave here passed its peak after the country added 621,317 cases on March 16.

Article continues after this advertisement

The decreases, however, have been slow and gradual due to the spread of the stealth Omicron subvariant, which is regarded as being more transmissible than the original Omicron variant.

Article continues after this advertisement

Despite steady decreases in the number of daily infections over the past few days, COVID-19 related deaths and critically ill patients continued to remain high.

Article continues after this advertisement

On Saturday, the country added 282 new COVID-19 deaths, down 41 from the previous day. The fatality rate came to 0.13 percent.

The number of critically ill patients reached 1,216, up from the previous day’s 1,164. The tally reported on Sunday was the second highest following 1,244 severe cases reported on March 16.

Article continues after this advertisement

The number of severe cases remained above 1,000 for 20 straight days since the country reported 1,007 severe cases on March 8.

The hospital bed occupancy rate for seriously ill COVID-19 patients also climbed 1.5 percent points from the previous day to reach 67.8 percent, or 1,915 out of 2,825 hospital beds available.

Meanwhile, the country’s health authorities on Saturday started to administer pharmaceutical company MSD’s oral antiviral medicine Lagevrio to severely ill COVID-19 patients.

The government said it will import antiviral medicines — Lagevrio and Pfizer’s antiviral treatment Paxlovid — for a total of 460,000 critically ill patients by the end of April.

RELATED STORIES

South Korea’s daily coronavirus cases stay below 400,000 for second day

S. Korea’s new COVID-19 cases above 300,000 for 4th day amid Omicron spread

South Korea’s new COVID-19 cases above 300,000 for 3rd day as Omicron rages

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

South Korea‘s daily COVID-19 cases stay over 350,000, critical cases rise

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, Health, South korea

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.